Ruvandhi Nathavitharana, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tuberculosis | 25 | 2024 | 2011 | 4.310 |
Why?
|
Tuberculosis, Pulmonary | 14 | 2024 | 836 | 3.570 |
Why?
|
Mycobacterium tuberculosis | 18 | 2022 | 1911 | 2.560 |
Why?
|
Tuberculosis, Multidrug-Resistant | 15 | 2021 | 941 | 2.390 |
Why?
|
Latent Tuberculosis | 4 | 2022 | 223 | 1.510 |
Why?
|
Disinfection | 3 | 2020 | 207 | 1.420 |
Why?
|
Sputum | 9 | 2024 | 514 | 0.980 |
Why?
|
Diagnostic Tests, Routine | 4 | 2024 | 789 | 0.940 |
Why?
|
Antibiotics, Antitubercular | 3 | 2021 | 100 | 0.930 |
Why?
|
Antitubercular Agents | 10 | 2021 | 1380 | 0.870 |
Why?
|
Breath Tests | 1 | 2024 | 297 | 0.850 |
Why?
|
Air Microbiology | 2 | 2020 | 94 | 0.830 |
Why?
|
Cough | 1 | 2024 | 599 | 0.700 |
Why?
|
Rifampin | 6 | 2021 | 350 | 0.700 |
Why?
|
Sensitivity and Specificity | 10 | 2024 | 14652 | 0.700 |
Why?
|
Contact Tracing | 1 | 2022 | 274 | 0.650 |
Why?
|
Knowledge | 1 | 2020 | 178 | 0.610 |
Why?
|
Occupational Diseases | 2 | 2017 | 1456 | 0.610 |
Why?
|
Measles | 2 | 2020 | 180 | 0.600 |
Why?
|
Nucleic Acid Amplification Techniques | 3 | 2021 | 335 | 0.590 |
Why?
|
Triage | 3 | 2024 | 995 | 0.580 |
Why?
|
Infection Control | 3 | 2020 | 984 | 0.570 |
Why?
|
Biological Assay | 1 | 2019 | 626 | 0.540 |
Why?
|
Consumer Advocacy | 1 | 2017 | 83 | 0.530 |
Why?
|
Sparganosis | 1 | 2015 | 4 | 0.500 |
Why?
|
Spirometra | 1 | 2015 | 4 | 0.500 |
Why?
|
Diffusion of Innovation | 1 | 2020 | 724 | 0.490 |
Why?
|
Microbial Sensitivity Tests | 4 | 2021 | 1972 | 0.490 |
Why?
|
Tick-Borne Diseases | 1 | 2015 | 37 | 0.470 |
Why?
|
Attitude to Health | 1 | 2021 | 2021 | 0.400 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3110 | 0.400 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3232 | 0.400 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2017 | 592 | 0.400 |
Why?
|
Breast Diseases | 1 | 2015 | 441 | 0.390 |
Why?
|
South Africa | 3 | 2022 | 1875 | 0.390 |
Why?
|
Nurses | 1 | 2021 | 2503 | 0.380 |
Why?
|
Cross Infection | 2 | 2017 | 1427 | 0.360 |
Why?
|
Drug Resistance, Bacterial | 3 | 2021 | 1065 | 0.350 |
Why?
|
Tuberculin Test | 2 | 2022 | 205 | 0.350 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2015 | 424 | 0.340 |
Why?
|
Pandemics | 2 | 2020 | 8735 | 0.340 |
Why?
|
Peru | 3 | 2024 | 888 | 0.340 |
Why?
|
Inpatients | 1 | 2018 | 2565 | 0.270 |
Why?
|
Health Personnel | 2 | 2017 | 3384 | 0.260 |
Why?
|
Sunlight | 1 | 2007 | 336 | 0.250 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 249 | 0.250 |
Why?
|
Disease Outbreaks | 1 | 2015 | 1761 | 0.250 |
Why?
|
Isoniazid | 2 | 2017 | 279 | 0.240 |
Why?
|
Humans | 53 | 2024 | 766766 | 0.240 |
Why?
|
Primary Health Care | 1 | 2021 | 4735 | 0.230 |
Why?
|
HIV Infections | 6 | 2022 | 17536 | 0.230 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2019 | 614 | 0.220 |
Why?
|
Physicians | 1 | 2021 | 4591 | 0.210 |
Why?
|
World Health Organization | 3 | 2020 | 1327 | 0.210 |
Why?
|
Disease Transmission, Infectious | 2 | 2020 | 560 | 0.210 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7431 | 0.200 |
Why?
|
Air Conditioning | 1 | 2020 | 54 | 0.170 |
Why?
|
Technology | 1 | 2021 | 296 | 0.160 |
Why?
|
Artificial Intelligence | 3 | 2022 | 2662 | 0.150 |
Why?
|
Carbon Dioxide | 1 | 2022 | 1138 | 0.150 |
Why?
|
Public Sector | 2 | 2016 | 265 | 0.150 |
Why?
|
Aerosols | 1 | 2020 | 634 | 0.140 |
Why?
|
Human Rights | 2 | 2017 | 312 | 0.140 |
Why?
|
Laboratory Personnel | 1 | 2017 | 19 | 0.140 |
Why?
|
Infectious Disease Transmission, Professional-to-Patient | 1 | 2017 | 33 | 0.140 |
Why?
|
Ethambutol | 1 | 2017 | 59 | 0.140 |
Why?
|
Mycobacterium avium-intracellulare Infection | 1 | 2017 | 82 | 0.130 |
Why?
|
Antigens, Bacterial | 1 | 2022 | 1148 | 0.130 |
Why?
|
National Health Programs | 1 | 2020 | 444 | 0.130 |
Why?
|
Tuberculosis, Osteoarticular | 1 | 2016 | 26 | 0.130 |
Why?
|
DNA Probes | 1 | 2017 | 541 | 0.130 |
Why?
|
Reference Standards | 1 | 2019 | 1010 | 0.130 |
Why?
|
Occupational Health Services | 1 | 2017 | 149 | 0.130 |
Why?
|
India | 3 | 2024 | 2335 | 0.130 |
Why?
|
Food Parasitology | 1 | 2015 | 6 | 0.130 |
Why?
|
Disease Susceptibility | 1 | 2022 | 1791 | 0.130 |
Why?
|
Anura | 1 | 2015 | 79 | 0.120 |
Why?
|
Praziquantel | 1 | 2015 | 34 | 0.120 |
Why?
|
Africa, Western | 1 | 2015 | 160 | 0.120 |
Why?
|
Antiparasitic Agents | 1 | 2015 | 41 | 0.120 |
Why?
|
Foodborne Diseases | 1 | 2015 | 41 | 0.120 |
Why?
|
Bangladesh | 1 | 2017 | 745 | 0.120 |
Why?
|
Immunity, Cellular | 1 | 2021 | 1560 | 0.120 |
Why?
|
Ethiodized Oil | 1 | 2014 | 26 | 0.120 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2019 | 698 | 0.120 |
Why?
|
Transients and Migrants | 1 | 2017 | 170 | 0.120 |
Why?
|
Ultraviolet Rays | 1 | 2019 | 1101 | 0.110 |
Why?
|
Early Diagnosis | 1 | 2019 | 1186 | 0.110 |
Why?
|
Counseling | 1 | 2022 | 1552 | 0.110 |
Why?
|
Food Contamination | 1 | 2015 | 193 | 0.110 |
Why?
|
Lipopolysaccharides | 1 | 2021 | 2214 | 0.110 |
Why?
|
Risk Factors | 4 | 2024 | 74881 | 0.110 |
Why?
|
Radiography, Abdominal | 1 | 2017 | 543 | 0.110 |
Why?
|
Emigration and Immigration | 1 | 2016 | 405 | 0.110 |
Why?
|
Climate Change | 1 | 2020 | 509 | 0.110 |
Why?
|
Optic Nerve Diseases | 1 | 2017 | 342 | 0.110 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2014 | 128 | 0.110 |
Why?
|
Knee Prosthesis | 1 | 2016 | 395 | 0.100 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1320 | 0.100 |
Why?
|
Quality of Health Care | 2 | 2019 | 4306 | 0.100 |
Why?
|
Health Services Accessibility | 4 | 2024 | 5514 | 0.100 |
Why?
|
Young Adult | 5 | 2024 | 59939 | 0.100 |
Why?
|
Health Services Needs and Demand | 2 | 2017 | 1404 | 0.100 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2014 | 755 | 0.100 |
Why?
|
Middle Aged | 10 | 2024 | 223257 | 0.100 |
Why?
|
Adult | 9 | 2024 | 223307 | 0.090 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5368 | 0.090 |
Why?
|
Hospitalization | 2 | 2024 | 10823 | 0.090 |
Why?
|
North America | 1 | 2015 | 1287 | 0.090 |
Why?
|
Antibodies, Neutralizing | 1 | 2021 | 2010 | 0.090 |
Why?
|
Drainage | 1 | 2017 | 1182 | 0.090 |
Why?
|
Retinal Ganglion Cells | 1 | 2017 | 810 | 0.090 |
Why?
|
Safety Management | 1 | 2016 | 765 | 0.090 |
Why?
|
Prosthesis-Related Infections | 1 | 2016 | 497 | 0.090 |
Why?
|
Conization | 1 | 2010 | 18 | 0.090 |
Why?
|
Prevalence | 2 | 2017 | 15835 | 0.090 |
Why?
|
Program Evaluation | 1 | 2019 | 2504 | 0.090 |
Why?
|
Prospective Studies | 3 | 2024 | 54871 | 0.080 |
Why?
|
Patient-Centered Care | 2 | 2017 | 1445 | 0.080 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2010 | 95 | 0.080 |
Why?
|
Antibodies, Viral | 1 | 2021 | 3212 | 0.080 |
Why?
|
Radiography, Interventional | 1 | 2017 | 1129 | 0.080 |
Why?
|
History, 21st Century | 1 | 2015 | 1574 | 0.080 |
Why?
|
China | 1 | 2015 | 2383 | 0.080 |
Why?
|
Emergencies | 1 | 2015 | 1223 | 0.080 |
Why?
|
Referral and Consultation | 1 | 2022 | 3618 | 0.080 |
Why?
|
Social Stigma | 1 | 2015 | 788 | 0.080 |
Why?
|
Cross-Sectional Studies | 3 | 2020 | 26310 | 0.080 |
Why?
|
Polymerase Chain Reaction | 1 | 2018 | 6066 | 0.080 |
Why?
|
Bacterial Infections | 1 | 2017 | 1390 | 0.080 |
Why?
|
Solar System | 1 | 2007 | 12 | 0.070 |
Why?
|
Anti-Infective Agents | 1 | 2015 | 987 | 0.070 |
Why?
|
Mycobacterium bovis | 1 | 2007 | 148 | 0.070 |
Why?
|
Occupational Exposure | 1 | 2017 | 1807 | 0.070 |
Why?
|
Incidence | 2 | 2022 | 21525 | 0.070 |
Why?
|
Equipment Contamination | 1 | 2007 | 183 | 0.070 |
Why?
|
Female | 9 | 2024 | 396520 | 0.060 |
Why?
|
Male | 9 | 2024 | 364142 | 0.060 |
Why?
|
Cohort Studies | 2 | 2019 | 41710 | 0.060 |
Why?
|
Risk | 1 | 2017 | 9602 | 0.060 |
Why?
|
SEER Program | 1 | 2010 | 1443 | 0.060 |
Why?
|
Hysterectomy | 1 | 2010 | 863 | 0.060 |
Why?
|
Child | 4 | 2019 | 80668 | 0.060 |
Why?
|
Research Design | 1 | 2019 | 6207 | 0.050 |
Why?
|
Students, Medical | 1 | 2017 | 1962 | 0.050 |
Why?
|
Private Sector | 2 | 2016 | 396 | 0.050 |
Why?
|
Specimen Handling | 1 | 2007 | 706 | 0.050 |
Why?
|
Genetic Variation | 1 | 2017 | 6612 | 0.050 |
Why?
|
Child, Preschool | 3 | 2019 | 42577 | 0.050 |
Why?
|
Quality Improvement | 1 | 2016 | 3850 | 0.050 |
Why?
|
X-Rays | 1 | 2022 | 309 | 0.050 |
Why?
|
Pulmonary Embolism | 1 | 2014 | 2596 | 0.040 |
Why?
|
Arthritis, Rheumatoid | 1 | 2016 | 3788 | 0.040 |
Why?
|
Health Policy | 3 | 2017 | 2698 | 0.040 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2021 | 238 | 0.040 |
Why?
|
Europe | 2 | 2017 | 3430 | 0.040 |
Why?
|
Equipment Design | 1 | 2007 | 3487 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2017 | 7475 | 0.040 |
Why?
|
Quality Assurance, Health Care | 2 | 2019 | 2171 | 0.040 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2010 | 2039 | 0.040 |
Why?
|
Mycobacterium avium Complex | 1 | 2017 | 66 | 0.030 |
Why?
|
Hospitals, General | 1 | 2021 | 804 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2018 | 570 | 0.030 |
Why?
|
Immunity, Humoral | 1 | 2021 | 608 | 0.030 |
Why?
|
Nitroimidazoles | 1 | 2017 | 118 | 0.030 |
Why?
|
Software | 2 | 2022 | 4466 | 0.030 |
Why?
|
Oxazoles | 1 | 2017 | 198 | 0.030 |
Why?
|
Policy | 1 | 2020 | 512 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2021 | 2921 | 0.030 |
Why?
|
Area Under Curve | 1 | 2019 | 1638 | 0.030 |
Why?
|
Retreatment | 1 | 2017 | 598 | 0.030 |
Why?
|
Retrospective Studies | 2 | 2021 | 81635 | 0.030 |
Why?
|
Adolescent | 3 | 2017 | 88904 | 0.030 |
Why?
|
Stem Cells | 1 | 2007 | 3537 | 0.030 |
Why?
|
Injections | 1 | 2017 | 839 | 0.030 |
Why?
|
Epidemics | 1 | 2020 | 516 | 0.030 |
Why?
|
Patient Care | 1 | 2020 | 629 | 0.030 |
Why?
|
Aged | 2 | 2024 | 171343 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2017 | 20708 | 0.030 |
Why?
|
Microscopy | 1 | 2016 | 902 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2018 | 1276 | 0.020 |
Why?
|
Program Development | 1 | 2016 | 1297 | 0.020 |
Why?
|
Communicable Disease Control | 1 | 2016 | 857 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2014 | 1838 | 0.020 |
Why?
|
Refugees | 1 | 2017 | 615 | 0.020 |
Why?
|
Odds Ratio | 1 | 2021 | 9661 | 0.020 |
Why?
|
Influenza, Human | 1 | 2020 | 1543 | 0.020 |
Why?
|
Radiography | 1 | 2019 | 6968 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2021 | 12430 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2016 | 26389 | 0.020 |
Why?
|
Time Factors | 1 | 2007 | 40149 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10745 | 0.010 |
Why?
|
Medication Adherence | 1 | 2016 | 2190 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2016 | 3561 | 0.010 |
Why?
|
Infant | 2 | 2016 | 36461 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2024 | 65273 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 10384 | 0.010 |
Why?
|
Infertility, Female | 1 | 2010 | 763 | 0.010 |
Why?
|
Health Care Costs | 1 | 2016 | 3242 | 0.010 |
Why?
|
Animals | 1 | 2015 | 168930 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15416 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2010 | 3609 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2018 | 59550 | 0.010 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2014 | 2326 | 0.010 |
Why?
|
Mass Screening | 1 | 2017 | 5454 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18397 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6512 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2014 | 4353 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2010 | 12534 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2010 | 11218 | 0.010 |
Why?
|